



Supplementary Fig. S1. Representative cases with discrepant human epidermal growth factor receptor 2 (HER2) classification between institutional and central reviews. (A) Case initially classified as HER2-null by institutional review but reclassified as HER2-ultralow by central review. Subtle membranous staining was identified on central review. (B) Case originally scored as HER2-ultralow by institutional review but reclassified as HER2-low by central review. The proportion of tumor cells showing incomplete membranous staining was estimated to exceed 10% on central review.